Capricor Therapeutics Inc (NASDAQ:CAPR) Receives $24.67 Consensus Target Price from Analysts

Capricor Therapeutics Inc (NASDAQ:CAPR) has been assigned a consensus rating of “Buy” from the six ratings firms that are presently covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $24.67.

Several research analysts have recently issued reports on the company. Maxim Group raised their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Oppenheimer reissued an “outperform” rating and set a $15.00 price target on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $8.00 price objective on shares of Capricor Therapeutics in a report on Friday, September 20th. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Capricor Therapeutics in a report on Wednesday, October 9th. Finally, Piper Sandler initiated coverage on shares of Capricor Therapeutics in a report on Monday, October 21st. They issued an “overweight” rating and a $35.00 price target on the stock.

Capricor Therapeutics Trading Up 4.5 %

NASDAQ CAPR opened at $19.70 on Wednesday. Capricor Therapeutics has a 12-month low of $2.68 and a 12-month high of $23.40. The company has a fifty day simple moving average of $13.81 and a two-hundred day simple moving average of $8.00. The stock has a market cap of $894.58 million, a P/E ratio of -21.18 and a beta of 4.00.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The firm had revenue of $3.97 million during the quarter, compared to analysts’ expectations of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. As a group, sell-side analysts forecast that Capricor Therapeutics will post -1.17 earnings per share for the current year.

Insider Activity at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the company’s stock in a transaction that occurred on Friday, September 20th. The shares were bought at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the transaction, the insider now owns 7,090,351 shares in the company, valued at $38,004,281.36. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 12.00% of the company’s stock.

Institutional Trading of Capricor Therapeutics

Several institutional investors have recently bought and sold shares of CAPR. BNP Paribas Financial Markets purchased a new position in Capricor Therapeutics in the 1st quarter worth approximately $40,000. Main Street Financial Solutions LLC increased its position in shares of Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after acquiring an additional 7,500 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Capricor Therapeutics during the third quarter valued at about $133,000. Rhumbline Advisers purchased a new stake in shares of Capricor Therapeutics in the 2nd quarter valued at approximately $147,000. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after acquiring an additional 9,040 shares during the last quarter. 21.68% of the stock is owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.